NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
NKGen Biotech, Inc. (NKGN)
Company Research
Source: GlobeNewswire
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format. E-Poster Details: Title:Therapeutic potential of expanded SNK01 (activated autologous natural killer cells) post-stroke to reduce neuroinflammation, inflammation-mediated cell death, and damageAuthors:Paul Y. Song, Lucia Hui, Blanca Isaura Acosta Gallo, César Alejandro Amescua, Katia Betito, Sean Hong, Clemente Humberto Zúñiga GilPoster Number:1389Session 1:Free
Show less
Read more
Impact Snapshot
Event Time:
NKGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKGN alerts
High impacting NKGen Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
NKGN
News
- NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceGlobeNewswire
- NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceGlobeNewswire
- NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a TrialGlobeNewswire
- NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly ReportGlobeNewswire